Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy

Borst, Jannie; Busselaar, Julia; Bosma, Douwe M T; Ossendorp, Ferry

doi:10.1002/eji.202048994

Cited by 40 publications

(37 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, clinical data have shown that PD-L1-targeted immunotherapy is effective in patients who do not express PD-L1 in the TIME [56]. Indeed, many authors suggest that PD-L1 blockade may also facilitate the de novo priming of tumor-specific CTLs in tdLNs [57].…”

Section: Pd-1/pd-l1 and Cancermentioning

confidence: 99%

Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?

Adorisio

Cannarile

Delfino

et al. 2021

Cells

View full text Add to dashboard Cite

Programmed cell death protein 1 (PD-1) and its ligands, PD-L1/2, control T cell activation and tolerance. While PD-1 expression is induced upon T cell receptor (TCR) activation or cytokine signaling, PD-L1 is expressed on B cells, antigen presenting cells, and on non-immune tissues, including cancer cells. Importantly, PD-L1 binding inhibits T cell activation. Therefore, the modulation of PD-1/PD-L1 expression on immune cells, both circulating or in a tumor microenvironment and/or on the tumor cell surface, is one mechanism of cancer immune evasion. Therapies that target PD-1/PD-L1, blocking the T cell-cancer cell interaction, have been successful in patients with various types of cancer. Glucocorticoids (GCs) are often administered to manage the side effects of chemo- or immuno-therapy, exerting a wide range of immunosuppressive and anti-inflammatory effects. However, GCs may also have tumor-promoting effects, interfering with therapy. In this review, we examine GC signaling and how it intersects with PD-1/PD-L1 pathways, including a discussion on the potential for GC- and PD-1/PD-L1-targeted therapies to “confuse” the immune system, leading to a cancer cell advantage that counteracts anti-cancer immunotherapy. Therefore, combination therapies should be utilized with an awareness of the potential for opposing effects on the immune system.

show abstract

Section: Pd-1/pd-l1 and Cancermentioning

confidence: 99%

Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?

Adorisio

Cannarile

Delfino

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…These molecules are recognized as immune checkpoints and are associated with immunosuppressive signals in the T cells of TME in a variety of cancers, including lung cancer, colon cancer, breast cancer, and melanoma. 19,20 HAVCR2, also known as TIM-3, is expressed on immune cells with enhanced suppressive functions, and is related to a poor disease prognosis in various cancers. 21 Interestingly, abundant MAIT cells are likely to make the anti-PD-1 treatment more effective in human metastatic melanoma.…”

Section: Discussionmentioning

confidence: 99%

The Study of Mucosal-Associated Invariant T Cells in Colon Cancer and Roles in Immune Activities

Mo¹,

Li²,

Gao³

et al. 2021

OTT

View full text Add to dashboard Cite

“…This therapy induces the immune system to kill tumor cells. This is why immunotherapy might solve the problem of tumor heterogeneity in targeted therapy [ 52 ]. The agents of immunotherapy are ICIs that have been helpful in several cancers [ 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

A novel pyroptosis-related gene signature to predict outcomes in laryngeal squamous cell carcinoma

Zhou

Zhan

Jin

et al. 2021

Aging

View full text Add to dashboard Cite

Pyroptosis, a pro-inflammatory form of programmed cell death, is associated with carcinogenesis and progression. However, there is little information concerning pyroptosis-related genes (PRGs) in laryngeal squamous cell carcinoma (LSCC). Herein, we aim to explore the prognostic value of PRGs in LSCC. The expression and clinical data of 47 PRGs in LSCC patients were obtained from The Cancer Genome Atlas. A novel prognostic PRG signature was constructed using least absolute shrinkage and selection operator analysis. Receiver operating characteristic (ROC) curves were drawn, and Kaplan-Meier survival Cox proportional hazard regression analyses were performed to measure the predictive capacity of the PRG signature. Furthermore, we constructed a six-PRG signature to divide LSCC patients into high- and low-risk groups. Patients in the high-risk group had worse overall survival than the low-risk group. The area under the time-dependent ROC curve was 0.696 for 1 year, 0.784 for 3 years, and 0.738 for 5 years. We proved that the PRGs signature was an independent predictor for LSCC. Functional enrichment analysis indicated that several immune-related pathways were significantly enriched in the low-risk group. Consistent with this, patients with low-risk scores had higher immune scores and better immunotherapeutic responses than the high-risk group. In conclusion, we established a novel PRGs signature that can predict outcome and response to immunotherapy of LSCC, pyroptosis may be a potential target for LSCC.

show abstract

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy

Cited by 40 publications

References 94 publications

Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?

Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?

The Study of Mucosal-Associated Invariant T Cells in Colon Cancer and Roles in Immune Activities

A novel pyroptosis-related gene signature to predict outcomes in laryngeal squamous cell carcinoma

Contact Info

Product

Resources

About